Literature DB >> 23362874

Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.

Joan A Puig-Butillé1, Celia Badenas, Zighereda Ogbah, Cristina Carrera, Paula Aguilera, Josep Malvehy, Susana Puig.   

Abstract

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS-related pathways are present in 87.5% of acral lentiginous melanomas.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362874      PMCID: PMC3563247          DOI: 10.1111/exd.12080

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  24 in total

1.  Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma.

Authors:  A Ruiz; S Puig; M Lynch; T Castel; X Estivill
Journal:  Int J Cancer       Date:  1998-05-04       Impact factor: 7.396

2.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

Authors:  Kian-Huat Lim; Antonio T Baines; James J Fiordalisi; Michail Shipitsin; Larry A Feig; Adrienne D Cox; Channing J Der; Christopher M Counter
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

3.  Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas.

Authors:  R Kumar; J Smeds; B Lundh Rozell; K Hemminki
Journal:  Melanoma Res       Date:  1999-04       Impact factor: 3.599

4.  Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.

Authors:  B C Bastian; M Kashani-Sabet; H Hamm; T Godfrey; D H Moore; E B Bröcker; P E LeBoit; D Pinkel
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

5.  The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

Authors:  Eiji Tanaka; Yosuke Hashimoto; Tetsuo Ito; Tomoyuki Okumura; Takatsugu Kan; Go Watanabe; Masayuki Imamura; Johji Inazawa; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

6.  A blueprint for staging of murine melanocytic lesions based on the Cdk4 ( R24C/R24C ) ::Tyr- NRAS ( Q ) ( 61K ) model.

Authors:  Elisabeth M T Wurm; Lynlee L Lin; Blake Ferguson; Duncan Lambie; Tarl W Prow; Graeme J Walker; H Peter Soyer
Journal:  Exp Dermatol       Date:  2012-06-29       Impact factor: 3.960

7.  Determinants of BRAF mutations in primary melanomas.

Authors:  Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

8.  Classifying melanocytic tumors based on DNA copy number changes.

Authors:  Boris C Bastian; Adam B Olshen; Philip E LeBoit; Daniel Pinkel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.

Authors:  Julia Reifenberger; Christiane B Knobbe; Astrid A Sterzinger; Britta Blaschke; Klaus W Schulte; Thomas Ruzicka; Guido Reifenberger
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

10.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.

Authors:  H Zhou; J Kuang; L Zhong; W L Kuo; J W Gray; A Sahin; B R Brinkley; S Sen
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  15 in total

Review 1.  Melanoma: clinical features and genomic insights.

Authors:  Elena B Hawryluk; Hensin Tsao
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

Review 2.  Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Authors:  Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley
Journal:  Semin Cancer Biol       Date:  2019-11-02       Impact factor: 15.707

3.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Authors:  Klaus G Griewank; Rajmohan Murali; Joan Anton Puig-Butille; Bastian Schilling; Elisabeth Livingstone; Miriam Potrony; Cristina Carrera; Tobias Schimming; Inga Möller; Marion Schwamborn; Antje Sucker; Uwe Hillen; Celia Badenas; Josep Malvehy; Lisa Zimmer; André Scherag; Susana Puig; Dirk Schadendorf
Journal:  J Natl Cancer Inst       Date:  2014-09-13       Impact factor: 13.506

Review 4.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

5.  Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.

Authors:  Gaurav Sharma; Christine G Lian; William M Lin; Ali Amin-Mansour; Judit Jané-Valbuena; Levi Garraway; Wendi Bao; Charles H Yoon; Nageatte Ibrahim
Journal:  J Cutan Pathol       Date:  2016-06-29       Impact factor: 1.587

6.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Authors:  Seungjae Lee; Raymond L Barnhill; Reinhard Dummer; James Dalton; Jianrong Wu; Alberto Pappo; Armita Bahrami
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

7.  Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.

Authors:  Letizia Porcelli; Gabriella Guida; Anna E Quatrale; Tiziana Cocco; Letizia Sidella; Immacolata Maida; Rosa M Iacobazzi; Anna Ferretta; Diana A Stolfa; Sabino Strippoli; Stefania Guida; Stefania Tommasi; Michele Guida; Amalia Azzariti
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

8.  Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling.

Authors:  MaKendra Umstead; Jinglin Xiong; Qi Qi; Yuhong Du; Haian Fu
Journal:  Oncotarget       Date:  2017-04-25

9.  Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.

Authors:  Junya Yan; Jiayi Yu; Xiaowen Wu; Tianxiao Xu; Huan Yu; Jie Dai; Meng Ma; Huan Tang; Longwen Xu; Zhihong Chi; Lu Si; Xinan Sheng; Chuanliang Cui; Yan Kong; Jun Guo
Journal:  J Cancer       Date:  2018-03-15       Impact factor: 4.207

Review 10.  Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.

Authors:  Patricia Basurto-Lozada; Christian Molina-Aguilar; Carolina Castaneda-Garcia; Martha Estefania Vázquez-Cruz; Omar Isaac Garcia-Salinas; Alethia Álvarez-Cano; Héctor Martínez-Said; Rodrigo Roldán-Marín; David J Adams; Patricia A Possik; Carla Daniela Robles-Espinoza
Journal:  Pigment Cell Melanoma Res       Date:  2020-06-17       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.